A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
Status:
Terminated
Trial end date:
2020-08-25
Target enrollment:
Participant gender:
Summary
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the
core study (CZPL389A2203/ NCT03517566) which is disclosed separately. It aimed to assess the
short-term and long-term safety of (blinded) 30 mg o.d and 50 mg o.d ZPL389 with concomitant
or intermittent use of topical corticosteroids (TCS) and/or topical calcineurin inhibitors
(TCI).